VEGFR affects miR-3200-3p-mediated regulatory T cell senescence in tumour-derived exosomes in non-small cell lung cancer
- PMID: 38363405
- DOI: 10.1007/s10142-024-01305-2
VEGFR affects miR-3200-3p-mediated regulatory T cell senescence in tumour-derived exosomes in non-small cell lung cancer
Abstract
Numerous studies have demonstrated that regulatory T (Treg) cells play an important role in the tumour microenvironment (TME). The aim of this study was to investigate whether VEGFR2 affects the expression of miR-3200-3p in exosomes secreted by tumour cells, thereby influencing Treg senescence in the TME. The results showed that VEGFR2 expression level was the highest in Calu-1 cells, and after transfection with si-VEGFR2, the exosomes secreted from Calu-1 cells were extracted and characterised with no significant difference from the exosomes of the untransfected group, but the expression of miR-3200-3p in the exosomes of the transfected si-VEGFR2 group was elevated. The Cell Counting Kit-8 (CCK-8) and flow cytometry (FCM) results suggested that exosomes highly expressing miR-3200-3p could inhibit Treg cell viability and promote apoptosis levels when treated with Treg cells. Detection of the senescence-associated proteins p16 INK4A and MMP3 by western blot (WB) revealed that exosomes highly expressing miR-3200-3p were able to elevate their protein expression levels. Tumour xenograft experiments demonstrated that exosomes with high miR-3200-3p expression promoted Treg cell senescence and inhibited subcutaneous tumour growth in nude mice. Dual-luciferase reporter assays and RNA pull-down assays showed that miR-3200-3p could be linked with DDB1. Overexpression of DDB1 reverses changes in DCAF1/GSTP1/ROS protein expression caused by exosomes with high miR-3200-3p expression. In conclusion, inhibition of VEGFR2 expression in tumour cells promotes the expression of miR-3200-3p in exosomes secreted by tumour cells. miR-3200-3p enters the TME through exosomes and acts on DDB1 in Treg cells to promote senescence of Treg cells to inhibit tumour progression.
Keywords: DDB1; NSCLC; Treg; VEGFR2; miRNA-3200-3p.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G (2019) Trends in the development of miRNA bioinformatics tools. Brief Bioinform 20:1836–1852. https://doi.org/10.1093/bib/bby054 - DOI - PubMed - PMC
-
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535–546. https://doi.org/10.1038/nrc3775 - DOI - PubMed - PMC
-
- Fisher SA, Aston WJ, Chee J et al (2016) Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis 5:16–28. https://doi.org/10.1002/iid3.136 - DOI - PubMed - PMC
-
- Guo H, Chang Z, Wu J, Li W (2019) Air pollution and lung cancer incidence in China: who are faced with a greater effect? Environ Int 132:105077. https://doi.org/10.1016/j.envint.2019.105077 - DOI - PubMed
-
- He C, Zheng S, Luo Y, Wang B (2018) Exosome theranostics: biology and translational medicine. Theranostics 8:237–255. https://doi.org/10.7150/thno.21945 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
